SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as widespread user frustration mounts over persistent platform outages and trading restrictions, especially with its ThinkorSwim platform. Despite recent positive financial updates and a substantial share buyback program, the community is actively discussing these reliability issues and the possibility of switching to alternative brokers.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is navigating intense investor speculation ahead of its earnings report, fueling a stark divide between bulls anticipating a significant short squeeze driven by its AI lending model and critics lamenting consistent underperformance and management's perceived lack of communication. The broader fintech sector's volatility and concerns over consumer credit health continue to weigh heavily on community sentiment, making the stock a focal point for both potential rebound and further weakness.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

CCCX is trending as Infleqtion, its quantum technology merger target, garners significant attention for its role in a NASA space mission and a U.S. Department of Energy contract, leading to community discussion around its perceived undervaluation against quantum peers and high expectations for its upcoming merger and NYSE debut as INFQ.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is rallying following its European CE Mark approval for the Eversense 365 CGM and the first commercial integration with the twiist automated insulin delivery system, with the community highly anticipating broader adoption of its superior one-year implantable technology despite historical management concerns and ongoing market volatility.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to a strong Q4 earnings beat and optimistic outlook, with the community highlighting reaccelerated revenue growth and surging RPO driven by both core and AI-native customers. This robust performance is viewed as a significant positive signal for the broader software sector, suggesting a potential end to its recent slowdown.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is trending sharply higher following positive top-line data from its Phase 2a trial for EVO301, an eczema drug, prompting widespread community discussion around significant upside potential and a short squeeze play, though some traders remain skeptical of its fundamentals.

American Superconductor Corp. engages in the provision of megawatt-scale power solutions. Its products include electric control systems, generators & drivetrains, power converters, renewable interconnectivity solutions, software, turbine designs, utility and industrial resilience and modernization solutions, and utility voltage solutions. It operates through the Grid and Wind segments. The Grid segment enables electric utilities and renewable energy project developers to connect, transmit, and distribute power with efficiency, reliability, security, and affordability. The Wind segment permits the manufacturers to field wind turbines with power output, reliability, and affordability. The company was founded by Yet Ming Chiang, David A. Rudman, John B. Vander Sande, and Gregory J. Yurek on April 9, 1987 and is headquartered in Ayer, MA.

American Superconductor Corp.

American Superconductor is trending as a strong financial quarter with robust guidance and a significant backlog sparks optimism, with many in the community viewing the stock as undervalued. Investors anticipate a rebound driven by its pivotal role in grid modernization, expanding defense contracts, and powering the rapidly growing AI data center sector.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending amidst a sharp stock decline following its Q4 earnings report, which revealed strong revenue growth and a substantial reduction in cash burn. This has sparked significant community discussion around whether the market is overlooking the company's fundamental improvements and clearer path to profitability.

Ichor Holdings Ltd. engages in designing, engineering, and manufacturing fluid delivery subsystems for semiconductor capital equipment. It offers gas and chemical delivery systems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The firm also manufactures precision machined components, weldments, and proprietary products for use in fluid delivery systems for direct sales to its customers. The company was founded in 1999 and is headquartered in Fremont, CA.

Ichor Holdings Ltd

Ichor Holdings is rallying sharply following strong Q4 earnings and robust revenue growth, driven by its critical fluid delivery systems for the semiconductor industry. The community is actively discussing its potential as a major beneficiary of increasing HBM and AI demand, further fueled by speculation around favorable implications from proposed semiconductor tariffs for US-based manufacturers.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atle Fund Management AB Purchases 36,402 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Atle Fund Management AB lifted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 23.2% in the 3rd quarter, according to its most recent Form 13F filing with...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven analysts that are currently covering the...

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,037,061.60 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 32,612 shares of the firm's stock in a transaction that occurred on Wednesday, January 28th. The...

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 39,816 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 39,816 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an...

Assessing NewAmsterdam Pharma Co: Insights From 5 Financial Analysts

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.5% - Time to Sell?

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 6.5% - What's Next...

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4% - Time to Sell?

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 6.4% - Here's What Happened...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Moderate Buy" from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten research firms that are covering the firm, MarketBeat reports. One...

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $2,719,986.57 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 75,117 shares of the firm's stock in a transaction on Tuesday, December 23rd. The stock was sold at an...

Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 75,117 shares of the company's stock in a transaction on Tuesday, December 23rd. The shares were sold...

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Current Price	$34.98
Prev Close	$35.00
Open	$35.19
Dividend Yield	0.00%
50-Day Moving Average	$34.57
Beta	0.97
Avg. Volume	698,496.85
PE Ratio	-17.14

52-Week High	$42.00
52-Week Low	$14.06
Market Capitalization	$3.97B
EPS (Annual)	-$2.56
Price to Book	5.44
Revenue Per Employee	$670,044.12
Enterprise Value/EBITDA	N/A

NAMS
NewAmsterdam Pharma Company NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NAMS News

NAMSNewAmsterdam Pharma Company NV